i remember a few months back, there was a 'Bunny' and then a morph into GriffinMingus. Read the posts and financial information provided. Took a small position in both MEMP and EROC, but then sold MEMP at a small profit and EROC at a small loss because the Saudis were not going to let up. Fast forward to today, many of us want to live in Southern France, eat and drink to our hearts content, put our feet in the water ... and if we knew that darn distribution (sorry about the reference to the divvie) was only going to get cut at worst 25% this would be a no brainer.
LOL ! tough to debate on a message board, but if you were sitting on some cash would you be throwing some of it at MEMP and/or ARP ? The temptation is almost killing me !
from shareholder_boar in an earlier thread:
If any patient now in a trial suffers a Serious Adverse Event then Celgene can, and very likely would, walk away. Although the safety data to date has been find, this class of drug can have troubles. The deal price is in the billions because the safety profile of the lead drug looks better than Gilenya's. If that is no longer the case then the value drops dramatically as it would be going up against generic Gilenya soon after launch.
A request for more information from the FTC relative to the required anti-trust approval would delay the close many months. Celgene was concerned enough about this that they included an unusual clause in the agreement permitting them to pay a fee and leave should there be a lengthy delay
no ... still watching it. the overall market volatility was working in my favor over the last few days. GL on ANIK tonite.
looks like there was at least 1 other serious bidder, and it was appropriately 'shopped'. there is still a chance another bidder surfaces.
July 27, 2015: Gilead Sciences, Inc. (Nasdaq:GILD) today announced the promotion of William Lee, PhD to Executive Vice President, Research, and Brett Pletcher to Executive Vice President and General Counsel. Dr. Lee and Mr. Pletcher will both join Gilead’s senior leadership committee
ha ha, thought you were taking the summer off fishing ! great move loading up on this one, Patchen. Good luck to you as well.
with respect to the SLXP takeover, SLXP traded below the VRX bid until the ENDP bid came along ... but the options told a very different story. Similar to what is going on here. Patience ....
First of all Celgene is a great company and i am sure many of the people at Receptos would be happy transitioning over. The fit is pretty interesting, it brings this part of the business into the line of fire of Biogen, and it would not surprise me one bit of Biogen raises the stakes just to force Celgene to pay market price (because we all know Celgene will pay more, the question is how much more). Kind of like what ENDP did to VRX during the Salix takeover drama which in effect forced VRX to pay closer to market value (which i was lucky to participate in after buying SLXP in November after the ignominious earnings call).
technically looking like it could hit .72, have been some at this level hoping I am wrong. With a US rate hike in the cards, that should strengthen the green back against the looney.